Navigation Links
American Orthopedic Spine Surgeon Successfully Treated for Autoimmune Arthritis with His Own Stem Cells
Date:1/26/2011

GERMANTOWN, Md., Jan. 26, 2011 /PRNewswire/ -- RNL BIO CO., LTD, a leading biopharmaceutical company specialized in adult stem cell therapeutics, announced on January 21, 2011 another successful patient report utilizing stem cell therapy on a leading US orthopedic spine surgeon who suffered from Autoimmune Arthritis.  

Dr. Stanley Jones, the surgeon and patient, reports that he had a sudden onset of acute pain in his wrist in September 2009; shortly thereafter the patient experiences pain in his knees as well.  Dr. Jones saw a rheumatologist who diagnosed him with Autoimmune Arthritis.  He was placed on Cortisone, a steroid hormone, to suppress immune response and alleviate pain.  Unfortunately Dr. Jones suffered complications from the Cortisone including chest pain and Candidiasis which were unbearable.  His condition deteriorated and his ability to perform routine activities of daily living or his profession was impacted.  

After visiting many physicians and talking with experts in the field, Dr. Jones was introduced to RNL Bio's stem cell therapy.  After a workup, he received stem cell infusions in Kyoto, Japan in May 2010.  Post infusion, he began to notice improvement and by the 5 month, he had a complete recovery and was able to resume sports as well as operating!  In addition, he no longer needed any medications including Cortisone or Methotrexate.  Dr. Jones' rheumatologist in Houston saw Dr. Jones post infusion and said, "It is amazing that Dr. Jones was able to experience improvement from cutting-edge medical technology."

Other patients treated by the company have had very successful results as reported by RNL BIO Co., Ltd in 2009, an American artist, John Cullison's stem cell treatment for Rheumatoid Arthritis, and in September 2010, Japanese Yosida's treatment for psoriasis.

About RNL BIO CO., LTD.

RNL BIO is a premier biotechnology company focused on the research and development of adult derived stem cell therapies.  RNL has two therapies in Phase II clinical trials for Buerger's Disease as well as Osteoarthritis and one phase I trial for spinal cord injury.  RNL is a publicly traded company on the Korean Stock Exchange (Code 003190) and is expanding its operations throughout the world.

Video Interview Link:

http://www.youtube.com/watch?v=xzDElPr9gRo

Related Link:

http://www.rnl.co.kr/eng/main.asp


'/>"/>
SOURCE RNL BIO CO., LTD.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. American Oriental Bioengineerings CEO and CFO Visit the United States as Entrepreneur Representatives of President Hu Jintaos Delegation
2. Maldonado Medicals Green Initiative, a Model for the American Small Business
3. American Medical Systems Launches STEP Patient Education Program in Europe
4. American Scientific Resources, Inc. Announces S-1 Registration Statement Effective; Commences Public Reporting Requirements
5. Amarin Announces Successful Completion of Offering of American Depositary Shares
6. Amarin Prices Public Offering of American Depositary Shares
7. Pharmacists Encourage Americans to Consider Medicine Cabinet Cleanout Among New Years Resolutions
8. CVS CAREMARK to Purchase Universal Americans Medicare Part D Business
9. American Regent Initiates Nationwide Voluntary Recall of Sodium Bicarbonate Injection, USP 7.5% and 8.4%, 50 mL Single Dose Vials Due to Particulate Matter
10. Frost & Sullivan Presents the 2010 North American Enabling Technology of the Year Award for Surface Functionalization Technologies to Semprus BioSciences
11. Red Cross Supports Pan American Health Organization with $1.5 Million in Medicine and Supplies for Cholera Response
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... YORK , May 25, 2016  According to ... reached $381 billion in 2015.  Though these are ... plenty of opportunity for success for companies that ... in search of new growth prospects medical device ... on research and development (R&D) than do companies ...
(Date:5/25/2016)... MedDay, a biotechnology company focused on the treatment of ... doses of biotin in progressive multiple sclerosis: extension phase results ... Ayman Tourbah , Principal Investigator of the Phase 3 study, ... (EAN) in Copenhagen, Denmark . The oral ... Sunday, 29 May 2016 from 14:45 to 16:15 CEST in ...
(Date:5/24/2016)... May 24, 2016   ... beide primären Endpunkte und demonstriert Ebenbürtigkeit ... ‚ausgezeichneter plus guter , ... ,      (Logo: http://photos.prnewswire.com/prnh/20130829/633895-a ... neue positive Daten von der MORA-Studie der Phase ...
Breaking Medicine Technology:
(Date:5/27/2016)... ... 27, 2016 , ... Each year Standard Process Inc. ... is this year’s Life University winner of a $2,500 scholarship from ... Leadership Awards ceremony. , Outerbridge is approaching her last quarter at Life University ...
(Date:5/26/2016)... ... ... last week’s media reports hinting at a June rate hike after the Federal Reserve’s ... interest rate increase, according to Rajeev Dhawan of the Economic Forecasting Center at Georgia ... (FOMC) dot charts are of interest to the press for their noise potential,” Dhawan ...
(Date:5/26/2016)... ... May 26, 2016 , ... W.S. Badger Co. Inc ., ... with a 2016 When Work Works Award for its use of effective workplace strategies ... When Work Works project administered by the Families and Work Institute (FWI) and the ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... ... and clinical outcomes, hosted members and suppliers for its inaugural Member Conference at ... on their mission of elevating the operational health of America’s healthcare providers. , ...
(Date:5/26/2016)... Chicago, Illinois (PRWEB) , ... May 26, 2016 , ... ... relationship with women’s basketball as a partner for the Tamika Catchings Legacy Tour ... , As the industry leader in hardwood basketball surfaces in all forms and levels ...
Breaking Medicine News(10 mins):